Canada-to-Australia cannabis exports represent one of the most rigorous bilateral supply pathways in the global medical cannabis market. The Australian medical channel sits behind a three-regulator stack: the Therapeutic Goods Administration (TGA), the Office of Drug Control (ODC), and the import permit framework embedded in the Therapeutic Goods Act 1989. For a Canadian Licensed Producer, navigating that stack requires simultaneous compliance with Health Canada export authorisation rules under the Cannabis Act and Australian product-quality requirements anchored in Therapeutic Goods Order No. 93 (TGO 93).
Australia has been one of the fastest-growing medical cannabis import markets since it legalised medicinal access in 2016. For Canadian LPs that have already built an export compliance infrastructure for Germany, the Australian pathway shares meaningful parallels in GMP expectations but diverges sharply on product standard specifications, access scheme pathways, and importer permit mechanics. Getting those differences wrong at the documentation stage is the most common cause of shipment holds at Australian customs. Australia's medical cannabis market reached AUD 445.6 million in 2025, a 53% year-on-year increase according to IBISWorld, with TGA SAS-B approvals totalling over 113,000 in the first half of 2025 alone, a market trajectory that makes regulatory precision at the entry point commercially significant.
This guide covers the complete export process: the Australian regulatory access pathways, the Health Canada export permit requirements, the TGO 93 quality specifications that Canadian product must meet, and the end-to-end operational sequence a Canadian LP should follow to get a first shipment cleared.
The Australian regulatory framework for medicinal cannabis imports
Three bodies govern medicinal cannabis imports into Australia, and a Canadian LP must understand each one's distinct role before approaching a potential importer partner.
The TGA is responsible for product approval and therapeutic access. Medicinal cannabis products reach Australian patients through one of three pathways:
- Special Access Scheme Category B (SAS-B): A prescriber applies on behalf of a specific patient to use an unapproved therapeutic good. SAS-B is the most common pathway for imported cannabis flower.
- Authorised Prescriber (AP): A medical practitioner receives TGA authorisation to prescribe a specific unapproved product to a class of patients without individual SAS-B applications. High-volume accounts rely on AP status.
- Product Registration (ARTG): Full registration on the Australian Register of Therapeutic Goods. Rare for cannabis flower; more relevant for finished pharmaceutical dose forms.
The Office of Drug Control (ODC) sits within the Department of Health and Aged Care. It administers import permits under the Therapeutic Goods Act 1989 and the Customs Regulations 1956. Every individual cannabis shipment into Australia requires a current ODC import permit issued to the Australian importer. These are shipment-specific, not standing permits. The ODC also licences domestic Australian cannabis businesses, and it is the counterpart to Health Canada in the bilateral notification process that underpins permit issuance.
The International Narcotics Control Board (INCB) sits above both. Australia's import permit system is built on the INCB import authorisation framework derived from the Single Convention on Narcotic Drugs, the same treaty framework that governs the German BfArM permit process. A Canadian LP that has worked through the German permit chain will recognise the structure. Canadian LPs exploring international market entry can review AlphaLeaf's international supply capabilities.
Health Canada export permit requirements for Australia
On the Canadian side, export authorisation is governed by Health Canada under the Cannabis Act and the Cannabis Regulations. The process is functionally the same as the German export pathway, with two key differences in documentation.
What Health Canada requires
The standard Health Canada cannabis export permit application requires:
- The applicant's Standard Cultivation licence (or processing licence if product is processed before export)
- The importing country's import authorisation or confirmation that the Australian ODC has issued or will issue an import permit (Health Canada accepts a draft ODC permit application as confirmation in practice)
- Product specifications: strain name, cannabinoid profile, batch number, estimated quantity in grams
- Destination importer details: name, address, and licence or registration number
- Proposed shipment date range
Health Canada processes export permit applications in 30 to 45 business days for first-time Australia routes. LPs with an established export history to Australia have reported faster processing. Permits are issued per shipment, not as standing authorisations, matching the ODC's own per-shipment permit structure.
Documentation the Australian importer needs from you
Before the ODC will issue an import permit, the Australian importer will typically request from the Canadian LP:
- A copy of the Health Canada export permit (or a draft if the ODC application precedes Health Canada approval)
- A current batch COA from an ISO/IEC 17025-accredited laboratory, with panels verified against TGO 93 specifications
- A copy of the LP's current GMP certificate issued by Health Canada, confirming scope covers cannabis flower for export (see AlphaLeaf's quality and process overview)
- A product specification sheet with THC/CBD potency, terpene profile, moisture content, and packaging format
This section was reviewed by Natalie Rousseau, AlphaLeaf's Australian Market Lead, who has managed supply into the Australian medical cannabis channel for six years and holds specialist knowledge of TGO 93, TGA SAS-B pathways, and ODC permit workflows.
Canadian LPs supplying AlphaLeaf's Montreal facility benefit from full batch traceability and ISO/IEC 17025-accredited testing on every lot, which directly satisfies this document package.
LPs seeking a compliant EU-GMP baseline should also review EU-GMP certification for Canadian cannabis LPs. Our Ice Cream Cake cultivar (30.3% THC, Wedding Cake x Gelato cross, large-bud hand-trimmed format) has been documented to TGO 93 panel specifications on request.TGO 93 quality specifications: what Canadian COAs must demonstrate
The most operationally significant compliance gap for Canadian LPs targeting Australia is TGO 93. While Health Canada's testing requirements are rigorous, TGO 93 imposes distinct limits and panel requirements that do not map directly to the Canadian domestic framework.
Microbiological limits
TGO 93 sets specific total aerobic microbial count (TAMC), total yeast and mould count (TYMC), and bile-tolerant gram-negative bacteria limits for inhaled cannabis products. The TGA's threshold for Aspergillus species (A. flavus, A. fumigatus, A. niger, A. terreus) is absence in 1g for products intended for immunocompromised patients. A COA that reports a combined mould count rather than species-specific Aspergillus data will not satisfy TGA review. LPs should instruct their ISO-accredited laboratory to run species-level Aspergillus identification as a standard component of every export lot tested for the Australian market.
Pesticide residues and heavy metals
TGO 93 adopts a comprehensive pesticide residue schedule that includes several compounds not listed in Health Canada's baseline pesticide panel. The heavy metals requirements under TGO 93 (arsenic, cadmium, lead, mercury) are consistent with Health Canada limits for most parameters, but the permissible limit for lead in cannabis flower under TGO 93 is set at a level that can differ from current Canadian practice. Labs running panels for dual-market export should confirm the precise limits against the current TGO 93 instrument before issuing the COA.
Moisture content and water activity
TGO 93 specifies acceptable moisture content ranges for dried cannabis flower. Australian importers and their dispensing pharmacies operate in a climate that differs substantially from Montreal indoor cultivation conditions, and product that arrives within Health Canada moisture limits may drift outside TGO 93 range if packaging is not optimised for humidity control during transit. This is a practical compliance issue that trip up first-shipment LPs: packaging design and moisture barrier selection must account for Australian conditions, not just the Canadian standard.
End-to-end operational process for a first shipment
A first Canada-to-Australia cannabis shipment typically takes four to six months from initial importer engagement to cleared customs delivery. The timeline below reflects the realistic sequencing for an LP with an existing Health Canada Standard Cultivation licence and export authorisation history.
Phase 1: Partner qualification (weeks 1 to 4)
Identify and qualify an Australian importer that holds an ODC import licence and active TGA prescriber approval or AP authorisation for the product category. Australian importer due diligence should include confirming the ODC licence number, verifying TGA prescriber approval status, and reviewing the importer's cold-chain and storage capabilities. The importer must be able to receive, store, and distribute cannabis flower in compliance with Australian scheduling and pharmacy regulations.
Phase 2: Documentation preparation (weeks 3 to 6, overlapping)
Prepare the full export document package:
- Current Health Canada GMP certificate (scope-confirmed)
- Batch COA with TGO 93-mapped panels from an ISO/IEC 17025-accredited lab
- Product specification sheet
- Proposed shipment quantities and packaging format
- Draft Health Canada export permit application
Share the document package with the Australian importer in full before either party submits permit applications. Mismatches between the Health Canada permit application and the ODC permit application are a common cause of delays.
Phase 3: Permit applications (weeks 5 to 12)
Submit the Health Canada export permit application. In parallel, the Australian importer submits the ODC import permit application, referencing the Canadian LP's Health Canada application number. ODC processing runs five to fifteen business days once complete. Health Canada processing for new Australia routes runs 30 to 45 business days. Both permits must be valid and in hand before the shipment is booked. Do not pre-book freight until both permits are confirmed.
Phase 4: Shipment and clearance (weeks 12 to 18)
Cannabis flower for Australia ships cold-chain or temperature-controlled, with packaging that meets both Health Canada labelling requirements under the Cannabis Regulations and TGO 93 product standard requirements. The commercial invoice, packing list, COA, Health Canada export permit, and ODC import permit travel with the shipment. Australian Border Force reviews the ODC permit on arrival. TGA may request supplementary COA documentation if batch parameters are not explicitly TGO 93-referenced. Plan for a 9 to 15 business day TGA compliance review window on first shipments. To discuss supply requirements for the Australian market, contact AlphaLeaf's international team or review our certifications and compliance documentation.
Frequently Asked Questions
The questions below cover the most common decision points for importers and LPs entering the Australia supply channel. For broader questions about AlphaLeaf's capabilities, visit our FAQ page.
Does Australia allow cannabis imports from Canada?
Yes. Australia permits medicinal cannabis imports from licensed foreign producers. A Canadian Licensed Producer must hold a valid Health Canada export authorisation under the Cannabis Act, and the Australian importer must hold an ODC import permit and an active TGA access scheme approval (SAS Category B or Authorised Prescriber) or a registered product pathway. Product must comply with TGO 93 quality specifications.
Does Canadian GMP satisfy Australia's GMP requirements for cannabis imports?
Australia's TGA recognises GMP certificates issued by Health Canada under the Mutual Recognition Agreement framework, but the recognition is conditional. The TGA evaluates whether the scope of the Canadian GMP certificate covers the specific dosage form and product type being imported. LPs should confirm their GMP certificate scope expressly covers dried cannabis flower for export before relying on Health Canada GMP recognition.
What is TGO 93 and why does it matter for Canadian exporters?
Therapeutic Goods Order No. 93 (TGO 93) is the Australian mandatory standard for medicinal cannabis products. It specifies permissible limits for microbiological contaminants, heavy metals, pesticide residues, and moisture content, as well as minimum testing requirements. Any cannabis imported into Australia for therapeutic use must comply with TGO 93. Canadian exporters must confirm their COA panels meet TGO 93 limits, not merely Health Canada limits, as certain parameters differ.
How long does the ODC import permit process take?
ODC import permits are issued per-shipment. Processing times typically range from five to fifteen business days once a complete application is submitted by the Australian importer. The Canadian exporter should align their Health Canada export permit timeline with the expected ODC permit issuance date, as both permits must be current at the time of shipment. ODC permits cannot be obtained in advance of a confirmed Canadian export permit.
What is the most common reason Canadian cannabis shipments are held at Australian customs?
The most common cause of holds is a COA that references Health Canada microbiological or contaminant limits rather than TGO 93 limits. Australian Border Force and TGA reviewers verify that the COA parameters and limits are TGO 93-compliant on their face. A COA that is accurate for Canadian domestic purposes but does not explicitly reference TGO 93 specifications will generate a customs query, and in some cases a hold pending retesting or supplementary documentation.
